Migraine is a primary neurological disorder characterized by high prevalence and high substantial disability. Although pharmacological intervention is essential for migraine prevention and treatment, it is plagued by several limitations such as suboptimal efficacy, frequent adverse drug reactions, and drug abuse,which may contribute to migraine chronification or medication overuse headache. Behavioral therapies such as cognitive behavioral therapy, biofeedback, and relaxation therapy have been increasingly recognized as complementary or alternative options to medication for migraine care in recent years. This article reviews current research progress on the clinical application and mechanisms of behavioral therapy in migraine management, with the aim of providing valuable insights for clinical practice.

Objective To investigate the expression level of the protein inhibitor of the activated STAT2(PIAS2)gene in prostate cancer and its relationship with clinicopathological features,and the potential role of PIAS2 in reprogramming lipid metabolism in prostate cancer.Methods The Cancer Genome Atlas Program(TCGA)database and HPA immunohistochemical analysis were used to show the expression of PIAS2 protein;qRT-PCR,Western bolt and immunohistochemistry were used to detect PIAS2 in prostate cancer tissues and their paracancerous tissues.PIAS2 expression in prostate cancer tissues and its paracancerous tissues and analyzed its relationship with clinicopathological features of patients;lentivirus infected prostate cancer cell line PC-3M,which stably knocked down PIAS2,was analyzed by ultra performance liquid chromatography mass spectrometry(UPLC-MS)for lipidomics.Results TCGA analysis showed that the expression of PIAS2 in prostate cancer tissues was higher than that in paracancerous tissues,and HPA immunohistochemistry analysis showed that PIAS2 protein was highly expressed in prostate cancer tissues;the expression of PIAS2 mRNA and protein was significantly elevated in prostate cancer compared with that in paracancerous tissues,and the difference was statistically significant(P<0.05);immunohistochemistry showed that PIAS2 protein Expression of PIAS2 protein was mainly localized in the nucleus of prostate,and the AOD value of prostate cancer tissues was significantly higher than that of paraneoplastic tissues:the results of clinicopathological parameters showed that PIAS2 had correlation with Gleason score and TNM stage(P<0.05),while there was no statistically significant correlation with the age of the patients,PSA and lymph node metastasis;UPLC-MS analysis suggested that the knockdown of PIAS2 affected 10 lipid changes,with down-regulation of phosphatidylcholine and phosphatidylethanolamine and up-regulation of phosphatidylinosi-tol,phosphatidylserine,diacylglycerol,and triacylglycerol in the shPIAS2 group compared with the shNC group.Conclusions The expression of PIAS2 protein was significantly elevated in prostate cancer tissues,suggesting that PIAS2 is associated with the development of prostate cancer,and its pathogenesis may be related to the abnormal lipid metabolism of prostate cancer.

Objective To investigate the expression level of the protein inhibitor of the activated STAT2(PIAS2)gene in prostate cancer and its relationship with clinicopathological features,and the potential role of PIAS2 in reprogramming lipid metabolism in prostate cancer.Methods The Cancer Genome Atlas Program(TCGA)database and HPA immunohistochemical analysis were used to show the expression of PIAS2 protein;qRT-PCR,Western bolt and immunohistochemistry were used to detect PIAS2 in prostate cancer tissues and their paracancerous tissues.PIAS2 expression in prostate cancer tissues and its paracancerous tissues and analyzed its relationship with clinicopathological features of patients;lentivirus infected prostate cancer cell line PC-3M,which stably knocked down PIAS2,was analyzed by ultra performance liquid chromatography mass spectrometry(UPLC-MS)for lipidomics.Results TCGA analysis showed that the expression of PIAS2 in prostate cancer tissues was higher than that in paracancerous tissues,and HPA immunohistochemistry analysis showed that PIAS2 protein was highly expressed in prostate cancer tissues;the expression of PIAS2 mRNA and protein was significantly elevated in prostate cancer compared with that in paracancerous tissues,and the difference was statistically significant(P<0.05);immunohistochemistry showed that PIAS2 protein Expression of PIAS2 protein was mainly localized in the nucleus of prostate,and the AOD value of prostate cancer tissues was significantly higher than that of paraneoplastic tissues:the results of clinicopathological parameters showed that PIAS2 had correlation with Gleason score and TNM stage(P<0.05),while there was no statistically significant correlation with the age of the patients,PSA and lymph node metastasis;UPLC-MS analysis suggested that the knockdown of PIAS2 affected 10 lipid changes,with down-regulation of phosphatidylcholine and phosphatidylethanolamine and up-regulation of phosphatidylinosi-tol,phosphatidylserine,diacylglycerol,and triacylglycerol in the shPIAS2 group compared with the shNC group.Conclusions The expression of PIAS2 protein was significantly elevated in prostate cancer tissues,suggesting that PIAS2 is associated with the development of prostate cancer,and its pathogenesis may be related to the abnormal lipid metabolism of prostate cancer.

Migraine is a primary neurological disorder characterized by high prevalence and high substantial disability. Although pharmacological intervention is essential for migraine prevention and treatment, it is plagued by several limitations such as suboptimal efficacy, frequent adverse drug reactions, and drug abuse,which may contribute to migraine chronification or medication overuse headache. Behavioral therapies such as cognitive behavioral therapy, biofeedback, and relaxation therapy have been increasingly recognized as complementary or alternative options to medication for migraine care in recent years. This article reviews current research progress on the clinical application and mechanisms of behavioral therapy in migraine management, with the aim of providing valuable insights for clinical practice.